Myocardial Ischemia

Disclaimer: This document provides comprehensive medical information for educational and reference purposes, modeled after clinical references like UpToDate. It is intended for healthcare professionals and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider based on the individual patient's condition, available evidence, and clinical judgment. Drug dosages and treatment protocols should be verified against current official prescribing information and local guidelines.

---

Overview

• Definition: Myocardial ischemia is a condition characterized by an imbalance between the myocardial oxygen supply and demand, leading to inadequate blood flow to the heart muscle. This deficit deprives the heart of oxygen and nutrients, impairing myocardial function.
• Epidemiology: Myocardial ischemia is predominantly caused by coronary artery disease (CAD), which affects millions globally. CAD is a leading cause of morbidity and mortality worldwide.
  • Prevalence increases with age, affecting approximately 6-7% of adults aged 20-59 and rising significantly to over 20% in those aged 60 and older.
  • Men generally develop CAD at a younger age than women, but incidence in women increases significantly post-menopause.
  • Ethnic disparities exist, with higher prevalence and severity in certain populations (e.g., South Asians, African Americans).
• Classification:
  • Stable Ischemic Heart Disease (SIHD) / Chronic Coronary Syndromes (CCS): Angina pectoris that occurs predictably with exertion or stress and is relieved by rest or nitroglycerin. Symptoms are stable over weeks to months.
  • Acute Coronary Syndromes (ACS): A spectrum of conditions involving acute myocardial ischemia, ranging from unstable angina to myocardial infarction.
    • Unstable Angina (UA): Angina at rest, new-onset severe angina, or crescendo (worsening) angina. No elevation of cardiac biomarkers.
    • Non-ST-Elevation Myocardial Infarction (NSTEMI): Myocardial ischemia sufficient to cause myocardial necrosis, evidenced by elevated cardiac biomarkers (e.g., troponin) but without persistent ST-segment elevation on ECG.
    • ST-Elevation Myocardial Infarction (STEMI): Myocardial ischemia with evidence of myocardial necrosis and persistent ST-segment elevation on ECG, indicating acute, complete, or near-complete coronary artery occlusion.

Pathophysiology

• Mechanism: The primary mechanism is reduced coronary blood flow due to:
  • Atherosclerosis: Formation of plaques within the coronary arteries, progressively narrowing the lumen and restricting blood flow.
  • Plaque Rupture and Thrombosis: The most common cause of ACS. An unstable atherosclerotic plaque ruptures, exposing thrombogenic material to the bloodstream, leading to platelet aggregation and thrombus formation, which can acutely occlude the artery.
  • Coronary Vasospasm: Transient, focal constriction of a coronary artery (Prinzmetal's angina), reducing blood flow. Can occur in the presence or absence of significant atherosclerosis.
  • Microvascular Dysfunction: Impaired function of small coronary arteries (e.g., Syndrome X), leading to ischemia despite epicardial coronary arteries being patent.
  • Supply-Demand Imbalance: Less commonly, ischemia can occur due to increased myocardial oxygen demand (e.g., severe aortic stenosis, hypertrophic cardiomyopathy, severe anemia, tachyarrhythmias, hyperthyroidism) in the absence of significant epicardial CAD, or due to critically reduced oxygen supply (e.g., severe anemia, hypoxemia).
• Risk Factors:
  • Modifiable:
    • Dyslipidemia: Elevated LDL cholesterol (>100 mg/dL optimal, <70 mg/dL in very high risk), low HDL cholesterol (<40 mg/dL), elevated triglycerides.
    • Hypertension: Sustained blood pressure ≥130/80 mmHg.
    • Diabetes Mellitus: Elevated fasting glucose (≥126 mg/dL), HbA1c ≥6.5%.
    • Smoking: Current smoking or exposure to secondhand smoke.
    • Obesity: BMI ≥30 kg/m² or waist circumference >102 cm (men), >88 cm (women).
    • Physical Inactivity: Lack of regular moderate-to-vigorous exercise.
    • Unhealthy Diet: High intake of saturated/trans fats, cholesterol, sodium, refined carbohydrates.
    • Stress/Psychosocial Factors: Chronic stress, depression, anxiety.
  • Non-Modifiable:
    • Age: Risk increases with age (men >45 years, women >55 years).
    • Sex: Males are at higher risk; post-menopausal women have increased risk.
    • Family History: First-degree relative with premature CAD (male <55 years, female <65 years).
    • Genetics: Predisposition to dyslipidemia, hypertension, diabetes.
• Protective Factors:
  • Regular physical activity (e.g., 150 minutes/week of moderate-intensity aerobic activity).
  • Healthy diet (e.g., Mediterranean, DASH diet).
  • Maintenance of healthy weight (BMI 18.5-24.9 kg/m²).
  • Smoking cessation.
  • Optimal control of blood pressure, lipids, and blood glucose.
  • Moderate alcohol consumption (if consumed).
  • Stress management.

Clinical Presentation

Signs and Symptoms

• Cardinal Features (Angina Pectoris):
  • Location: Typically substernal, but may radiate to the left arm, shoulder, back, neck, jaw, or epigastrium.
  • Character: Pressure, squeezing, tightness, heaviness, crushing sensation, burning. Not sharp, pleuritic, or positional. Often described as "indigestion" or "heartburn."
  • Duration: Usually lasts 2-10 minutes (stable angina), but can be longer (>20 minutes in ACS).
  • Precipitating Factors: Exertion, emotional stress, cold weather, heavy meals.
  • Relieving Factors: Rest, sublingual nitroglycerin (typically within 1-5 minutes for stable angina).
  • Associated Symptoms: Dyspnea, diaphoresis, nausea, lightheadedness, fatigue.
  • Levine's Sign: Patient clenches a fist over their chest to describe the pain.
• Early Signs:
  • Angina on moderate exertion (e.g., walking uphill, carrying groceries).
  • Exertional dyspnea (anginal equivalent).
• Advanced Signs:
  • Angina at rest or with minimal exertion.
  • Nocturnal angina.
  • Crescendo angina (increasing frequency, intensity, or duration of pain).
  • Prolonged chest pain (>20 minutes) suggestive of ACS.
• Atypical Presentations: More common in women, elderly, diabetics, and those with chronic kidney disease.
  • Symptoms: Dyspnea (without chest pain), profound fatigue, weakness, indigestion, nausea/vomiting, lightheadedness, upper back pain, isolated arm/jaw/neck pain.
  • Silent Ischemia: No symptoms despite objective evidence of ischemia (e.g., on ECG or stress testing). Common in diabetics and elderly.

Physical Examination

Physical findings in myocardial ischemia are often non-specific or absent in stable angina, but can indicate severity or complications in ACS.

• Inspection:
  • Signs of distress (anxiety, agitation).
  • Diaphoresis (sweating), pallor.
  • Signs of heart failure (e.g., elevated jugular venous pressure, peripheral edema, cyanosis).
• Palpation:
  • Tachycardia or bradycardia.
  • Irregular pulse (arrhythmia).
  • Hypotension or hypertension.
  • Precordial heave or thrills (rare, suggest severe dysfunction or mechanical complications).
• Auscultation:
  • Heart Sounds: Presence of S3 (systolic dysfunction/heart failure) or S4 (LV stiffness/ischemia).
  • Murmurs: New or worsening holosystolic murmur (mitral regurgitation due to papillary muscle dysfunction or rupture).
  • Lung Sounds: Crackles or rales (pulmonary edema suggestive of left ventricular failure).
  • Pericardial Friction Rub: (rare, suggests pericarditis, potentially post-MI).
• Special Tests: No specific maneuvers directly elicit ischemia. The physical exam focuses on assessing hemodynamic stability, signs of heart failure, and ruling out other causes of chest pain.

Diagnostic Approach

History Taking

• Key Questions:
  • Palliative/Provocative: What brings on the pain? What makes it better? (Exertion, rest, nitroglycerin)
  • Quality: What does it feel like? (Pressure, tightness, burning, sharp, pleuritic)
  • Radiation: Does it spread anywhere? (Left arm, jaw, back)
  • Severity: On a scale of 0-10?
  • Timing: When did it start? How long does it last? Is it constant or intermittent? Has it changed in pattern (frequency, intensity, duration)?
  • Associated Symptoms: Shortness of breath, sweating, nausea, dizziness, palpitations.
  • Risk Factors: Personal and family history of CAD, hypertension, diabetes, dyslipidemia, smoking, obesity.
  • Previous Cardiac History: Prior MI, PCI, CABG, heart failure, arrhythmias.
• Red Flags:
  • Chest pain at rest or with minimal exertion.
  • New-onset angina or rapidly worsening (crescendo) angina.
  • Angina unresponsive to nitroglycerin.
  • Associated symptoms of hemodynamic instability (syncope, severe dyspnea, shock).
  • Chest pain with ST-segment elevation on ECG.
  • Recurrent chest pain after initial improvement.

Laboratory Tests

• First-Line (for suspected ACS):
  • Cardiac Troponin I or T (high-sensitivity): Preferred biomarker for myocardial necrosis. Levels typically rise within 3-6 hours of injury, peak at 12-24 hours, and can remain elevated for days. Serial measurements (e.g., at presentation and 1-3 hours later for hs-Tn, or 3-6 hours later for conventional Tn) are crucial for diagnosis.
    • Cutoff: Manufacturer-specific, usually the 99th percentile of a healthy reference population. A rise and/or fall is diagnostic.
  • Creatine Kinase-MB (CK-MB): Less sensitive and specific than troponin, but may be used in conjunction or for re-infarction detection (rises earlier).
  • Complete Blood Count (CBC): Assess for anemia (can worsen ischemia) and infection (rule out other causes).
  • Basic Metabolic Panel (BMP): Electrolytes (potassium, magnesium), renal function (creatinine, BUN) for medication dosing and risk stratification.
  • Lipid Panel: Fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) for risk factor assessment and baseline.
  • HbA1c: For diabetes assessment.
• Confirmatory (for stable ischemia):
  • Stress Testing: If initial ACS workup is negative, and patient is stable.
    • Exercise ECG Stress Test: For patients able to exercise and with interpretable resting ECG. Positive if ≥1 mm horizontal or downsloping ST-segment depression at 80 ms after J-point.
    • Stress Echocardiography: Detects regional wall motion abnormalities during stress.
    • Myocardial Perfusion Imaging (MPI): Using SPECT or PET with a tracer (e.g., Technetium-99m sestamibi, Thallium-201) to identify inducible ischemia (reversible perfusion defects).
    • Pharmacologic Stress Tests: For patients unable to exercise (e.g., Dobutamine for echo, Adenosine/Regadenoson for MPI).
  • Coronary Angiography: Gold standard for visualizing coronary artery anatomy and identifying stenoses. Indicated for high-risk ACS, persistent symptoms despite medical therapy, or positive non-invasive stress tests.
• Monitoring:
  • Serial cardiac biomarkers (for ACS).
  • Electrolytes, renal function (with diuretic/ACEi use).
  • Lipid panel (for statin therapy efficacy).
  • HbA1c (for diabetes control).

Imaging

• Recommended:
  • 12-Lead Electrocardiogram (ECG): Obtained immediately (within 10 minutes) for suspected ACS.
    • STEMI: Persistent ST-segment elevation ≥1 mm in ≥2 contiguous leads (or ≥2 mm in V2-V3) or new LBBB.
    • NSTEMI/UA: ST-segment depression, T-wave inversion, or non-specific changes. May be normal in up to 30% of UA/NSTEMI.
  • Chest X-ray (CXR): To rule out alternative causes of chest pain (e.g., pneumonia, pneumothorax, aortic dissection) and assess for signs of heart failure (e.g., pulmonary edema).
  • Echocardiography (Transthoracic): Assess global and regional left ventricular function, evaluate for valvular disease, pericardial effusion, and rule out structural heart disease. Can identify wall motion abnormalities indicative of ischemia/infarction.
• Advanced:
  • Coronary CT Angiography (CCTA): Non-invasive imaging of coronary arteries to detect plaque and stenosis. Useful for low-to-intermediate probability chest pain, or when stress tests are equivocal. Can provide Calcium Score (Agatston score) to quantify coronary calcification.
  • Cardiac Magnetic Resonance (CMR): Provides detailed assessment of myocardial viability, perfusion, scar tissue (late gadolinium enhancement), and cardiac function. Useful in cases of non-ischemic cardiomyopathy or when other imaging is inconclusive.
  • Invasive Coronary Angiography (Cardiac Catheterization): Definitive diagnostic test for CAD, providing detailed images of coronary artery lumens. Essential for revascularization procedures (PCI).

Management

Acute Management (for ACS)

• Immediate (within minutes of presentation):
  • Initial Assessment: Rapid assessment of ABCs (Airway, Breathing, Circulation).
  • ECG: Obtain 12-lead ECG within 10 minutes.
  • IV Access: Establish intravenous access.
  • Labs: Draw blood for cardiac biomarkers, CBC, chemistry.
  • Aspirin: Administer chewable Aspirin 162-325 mg (non-enteric coated).
  • Nitroglycerin (NTG): Sublingual (SL) NTG 0.4 mg every 5 minutes for up to 3 doses if systolic BP >90 mmHg and no right ventricular infarction suspected. IV NTG for persistent ischemia, heart failure, or hypertension.
  • Oxygen: Administer if SaO2 <90% or patient is dyspneic/hypoxemic (typically 2-4 L/min via nasal cannula). Avoid routine oxygen in non-hypoxemic patients.
  • Morphine: For severe pain unresponsive to NTG, 2-4 mg IV titrated every 5-15 minutes. Use cautiously due to potential for hypotension and nausea.
• Stabilization (within hours):
  • Antiplatelet Therapy:
    • Dual Antiplatelet Therapy (DAPT): Aspirin daily (e.g., 81 mg) plus a P2Y12 inhibitor.
    • P2Y12 Inhibitors:
      • Clopidogrel: 300-600 mg loading dose, then 75 mg daily.
      • Ticagrelor: 180 mg loading dose, then 90 mg BID. (Preferred over clopidogrel for most ACS).
      • Prasugrel: 60 mg loading dose, then 10 mg daily. (Contraindicated in history of stroke/TIA, not for patients ≥75 years or <60 kg unless benefits outweigh risks).
  • Anticoagulation:
    • Unfractionated Heparin (UFH): IV bolus then infusion, adjusted by aPTT.
    • Low Molecular Weight Heparin (LMWH, e.g., Enoxaparin): 1 mg/kg SC every 12 hours (or 1 mg/kg once daily for CrCl <30 mL/min).
    • Bivalirudin: For patients undergoing PCI.
  • Beta-blockers: Oral beta-blocker (e.g., Metoprolol, Carvedilol) initiated within 24 hours in stable patients without acute heart failure, low cardiac output, or risk of cardiogenic shock. IV beta-blockers usually reserved for hypertensive patients without contraindications.
  • Statins: High-intensity statin (e.g., Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg) initiated as early as possible.
  • Risk Stratification: TIMI, GRACE scores to assess risk of death/MI and guide management.
• Emergency (for STEMI and high-risk NSTEMI):
  • Reperfusion Strategy (STEMI):
    • Primary Percutaneous Coronary Intervention (PCI): Preferred if achievable within 90 minutes (door-to-balloon time) or 120 minutes of first medical contact.
    • Fibrinolysis: If PCI cannot be performed within recommended time frames (e.g., Alteplase, Tenecteplase, Reteplase). Administer within 30 minutes (door-to-needle time). Follow with transfer to PCI-capable center.
  • Invasive Strategy (NSTEMI):
    • Early Invasive (within 24 hours): For high-risk NSTEMI patients (e.g., elevated troponin, dynamic ECG changes, hemodynamic instability, recurrent angina despite medical therapy, new/worsening mitral regurgitation, LVEF <40%).
    • Delayed/Selective Invasive: For low-to-intermediate risk NSTEMI.

Chronic Management (for SIHD/CCS)

• Pharmacological:
  • Antiplatelet Therapy:
    • Aspirin: 75-100 mg daily for life unless contraindicated.
  • Anti-anginal Medications (Symptom Control):
    • Beta-blockers: First-line for stable angina (e.g., Metoprolol extended-release 25-200 mg daily, Atenolol 25-100 mg daily, Bisoprolol 2.5-10 mg daily). Titrate to target heart rate 55-60 bpm at rest.
    • Nitrates:
      • Sublingual (SL) NTG: 0.4 mg PRN for acute angina.
      • Long-acting Nitrates: Isosorbide mononitrate (e.g., 30-120 mg daily ER), Isosorbide dinitrate (e.g., 10-40 mg BID-TID with nitrate-free interval). For persistent symptoms.
    • Calcium Channel Blockers (CCBs):
      • Dihydropyridines (e.g., Amlodipine 5-10 mg daily, Nifedipine ER): Primarily for vasospastic angina or when beta-blockers are contraindicated/ineffective. Can be combined with beta-blockers.
      • Non-dihydropyridines (e.g., Diltiazem 120-360 mg daily ER, Verapamil 120-480 mg daily ER): Can be used if beta-blockers are contraindicated. Avoid combination with beta-blockers due to risk of bradycardia/AV block.
    • Ranolazine: 500-1000 mg BID. Can be added to beta-blockers or CCBs for persistent angina.
  • Lipid-Lowering Therapy:
    • Statins: High-intensity statins (Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg) for all patients with SIHD, aiming for LDL-C <70 mg/dL or a ≥50% reduction.
    • Ezetimibe, PCSK9 inhibitors: If LDL-C targets not met with maximally tolerated statin.
  • ACE Inhibitors / ARBs: Recommended for all patients with CAD and hypertension, diabetes, LVEF ≤40%, or chronic kidney disease. (e.g., Lisinopril 10-40 mg daily, Ramipril 2.5-10 mg daily).
• Non-pharmacological:
  • Lifestyle Modification:
    • Smoking Cessation: Crucial.
    • Diet: Heart-healthy diet (e.g., Mediterranean, DASH diet), low in saturated/trans fats, cholesterol, sodium.
    • Exercise: Regular moderate-intensity aerobic exercise (e.g., 30-60 minutes, 5-7 days/week).
    • Weight Management: Maintain BMI 18.5-24.9 kg/m².
    • Blood Pressure Control: Target <130/80 mmHg.
    • Diabetes Control: HbA1c <7.0%.
  • Cardiac Rehabilitation: Comprehensive, multidisciplinary program including exercise training, education, and counseling. Improves exercise capacity, reduces symptoms, and enhances quality of life.
• Monitoring:
  • Regular clinical follow-up (e.g., every 3-6 months initially, then annually).
  • Symptom assessment (angina frequency, severity, nitroglycerin use).
  • Blood pressure monitoring, lipid panel, HbA1c.
  • Consider periodic stress testing or re-evaluation if symptoms worsen or change.

Treatment Algorithms

• First-Line (SIHD):
  1. Lifestyle Modifications: Smoking cessation, diet, exercise, weight control.
  2. Pharmacotherapy:
     • Aspirin 75-100 mg daily.
     • High-intensity Statin.
     • Beta-blocker (first-line for symptom control, titrate to effect).
     • Sublingual Nitroglycerin PRN.
     • ACE Inhibitor/ARB (if indicated for HTN, DM, LV dysfunction).
• Second-Line (SIHD, for persistent symptoms):
  1. If beta-blocker ineffective or not tolerated: Add/switch to long-acting CCB (dihydropyridine or non-dihydropyridine).
  2. If angina persists on dual therapy (beta-blocker + CCB or high-dose single agent): Add Ranolazine.
  3. Consider revascularization (PCI or CABG) if symptoms are refractory to optimal medical therapy, or if high-risk anatomical features are identified (e.g., left main disease, multi-vessel disease with reduced LVEF). Decision based on patient preference, severity of symptoms, and extent of ischemia/anatomy.
• Refractory Cases:
  • Enhanced External Counterpulsation (EECP): Non-invasive treatment for chronic refractory angina.
  • Spinal Cord Stimulation: May be considered for highly selected patients.
  • Specialized Pain Clinics: For chronic pain management.
  • Consideration for repeat revascularization: If significant new or progressive stenoses.

Complications

• Common:
  • Recurrent angina pectoris.
  • Arrhythmias (e.g., ventricular arrhythmias, atrial fibrillation, bradycardia).
  • Heart failure (due to ischemic cardiomyopathy or myocardial infarction).
  • Recurrent Acute Coronary Syndromes (UA, NSTEMI, STEMI).
• Serious:
  • Myocardial Infarction: Permanent damage to heart muscle.
  • Cardiogenic Shock: Severe pump failure leading to inadequate tissue perfusion, often post-MI.
  • Cardiac Arrest / Sudden Cardiac Death: Often due to ventricular arrhythmias.
  • Mechanical Complications of MI:
    • Ventricular Septal Rupture (VSR).
    • Papillary Muscle Rupture (leading to severe mitral regurgitation).
    • Cardiac Free Wall Rupture (usually fatal).
  • Pericarditis (Dressler's Syndrome): Autoimmune reaction post-MI.
  • Ventricular Aneurysm: Late complication of transmural MI.
• Long-term:
  • Chronic Heart Failure.
  • Chronic debilitating angina.
  • Post-MI depression and anxiety.
  • Need for repeat revascularization procedures.

Prognosis

• Factors:
  • Extent and Severity of CAD: Single-vessel vs. multi-vessel disease, presence of left main coronary artery disease.
  • Left Ventricular Ejection Fraction (LVEF): Lower LVEF (e.g., <40%) significantly worsens prognosis.
  • Presence of Comorbidities: Diabetes mellitus, chronic kidney disease, peripheral artery disease, cerebrovascular disease.
  • Clinical Presentation: ACS (especially STEMI) carries higher short-term mortality than stable angina.
  • Adherence to Medical Therapy and Lifestyle Changes: Crucial for long-term prognosis.
  • Completeness of Revascularization: Improves outcomes.
• Survival: Prognosis for stable CAD has significantly improved with modern medical therapy and revascularization. However, CAD remains a leading cause of mortality. Five-year mortality for stable angina is approximately 5-10%, but much higher for ACS (e.g., 30-day mortality for STEMI can be 5-10% even with revascularization).
• Quality of Life: Can be significantly impaired by persistent angina, dyspnea, limitations in physical activity, and psychological distress (anxiety, depression). Optimal medical therapy and cardiac rehabilitation aim to improve symptom control and functional status.

Prevention

• Primary Prevention: Preventing the initial occurrence of CAD and myocardial ischemia.
  • Aggressive Risk Factor Modification:
    • Blood Pressure Control: Maintain BP <130/80 mmHg (or individualized target).
    • Lipid Management: Achieve optimal LDL-C levels based on risk assessment (e.g., <100 mg/dL for moderate risk, <70 mg/dL for high risk, <55 mg/dL for very high risk with ASCVD).
    • Diabetes Management: HbA1c <7.0%.
    • Smoking Cessation: Eliminate all tobacco use.
    • Healthy Diet: DASH or Mediterranean diet (rich in fruits, vegetables, whole grains, lean protein, healthy fats; low in saturated/trans fats, cholesterol, sodium, added sugars).
    • Regular Physical Activity: At least 150 minutes/week of moderate-intensity or 75 minutes/week of vigorous-intensity aerobic activity.
    • Weight Management: Maintain healthy BMI (18.5-24.9 kg/m²).
  • Aspirin: Not routinely recommended for primary prevention in low-risk individuals due to bleeding risk. May be considered for select high-risk patients without increased bleeding risk (individualized decision).
• Secondary Prevention: Preventing recurrent events and complications in individuals with established CAD.
  • Pharmacotherapy:
    • Aspirin: 75-100 mg daily for life (or DAPT as indicated post-ACS/PCI).
    • Statins: High-intensity statin for life.
    • Beta-blockers: Post-MI with LV dysfunction, or for symptom control.
    • ACE Inhibitors / ARBs: Post-MI with LV dysfunction, or with hypertension/diabetes.
    • SGLT2 Inhibitors / GLP-1 Receptor Agonists: For patients with T2DM and established ASCVD to reduce CV events.
  • Comprehensive Cardiac Rehabilitation: Essential post-ACS or revascularization.
  • Aggressive Risk Factor Control: Continued emphasis on lifestyle modifications and optimal medical management of all modifiable risk factors.
• Tertiary Prevention: Preventing complications and improving quality of life in patients with advanced disease or chronic sequelae.
  • Adherence to long-term medical therapy.
  • Symptom management (e.g., chronic angina management).
  • Regular follow-up with cardiology.
  • Management of heart failure or arrhythmias.

Special Populations

• Pediatric: Myocardial ischemia is rare in children and often due to:
  • Congenital coronary artery anomalies (e.g., anomalous left coronary artery from the pulmonary artery - ALCAPA).
  • Kawasaki disease (leading to coronary artery aneurysms).
  • Metabolic disorders (e.g., familial hypercholesterolemia).
  • Post-cardiac surgery complications.
  • Symptoms can be non-specific (irritability, feeding difficulties, poor growth, syncope). Diagnosis requires high index of suspicion.
• Geriatric:
  • Atypical presentations of ischemia are common (e.g., dyspnea, fatigue, syncope, confusion, or silent ischemia).
  • Higher prevalence of comorbidities and polypharmacy, increasing risk of drug interactions and side effects.
  • Increased risk of complications post-MI (e.g., heart failure, cardiogenic shock, mechanical complications).
  • Treatment decisions require careful consideration of frailty, life expectancy, and patient preferences. Beta-blockers and statins remain beneficial, but titration needs caution.
• Pregnancy:
  • Myocardial ischemia in pregnancy is rare but increasing. Causes include:
    • Spontaneous Coronary Artery Dissection (SCAD): More common in pregnancy/postpartum.
    • Peripartum cardiomyopathy.
    • Accelerated atherosclerosis in women with pre-existing risk factors (e.g., familial hypercholesterolemia, pre-eclampsia).
  • Diagnosis and management are challenging due to physiologic changes of pregnancy and concerns for fetal safety.
  • Medical therapy requires careful drug selection (e.g., Aspirin generally safe, statins contraindicated, ACEi/ARBs contraindicated).
  • PCI can be performed with fetal shielding, but fibrinolysis is generally avoided.
• Comorbidities:
  • Diabetes Mellitus: Increased risk of silent ischemia, diffuse CAD, and poorer outcomes. Requires aggressive risk factor modification and consideration of SGLT2 inhibitors/GLP-1 agonists.
  • Chronic Kidney Disease (CKD): Significantly increases CAD risk and mortality. Diagnosis can be challenging (atypical symptoms, elevated troponin due to renal dysfunction, challenges with contrast). Management requires careful medication dosing and often early invasive strategy due to higher risk profile.
  • Chronic Obstructive Pulmonary Disease (COPD): Can complicate beta-blocker use (though cardio-selective beta-blockers are generally safe). Chest pain differentiation can be difficult.

Clinical Pearls

• Diagnostic:
  • "Time is muscle": In ACS, particularly STEMI, rapid diagnosis and reperfusion are paramount.
  • Always obtain a 12-lead ECG within 10 minutes for any patient presenting with chest pain suggestive of ACS.
  • High-sensitivity troponin assays are now standard and allow for earlier rule-in or rule-out. Serial measurements are key.
  • Don't be fooled by atypical presentations, especially in women, diabetics, and the elderly. A high index of suspicion is critical.
  • A normal ECG does NOT rule out unstable angina or NSTEMI.
• Treatment:
  • MONA is a mnemonic, but not necessarily the order of operations. Aspirin first. Oxygen only if hypoxemic. Morphine for severe pain not relieved by NTG.
  • Optimal Medical Therapy (OMT) is the cornerstone of chronic management, even in patients who undergo revascularization.
  • Aggressive risk factor modification, especially smoking cessation, significantly improves long-term outcomes.
  • Dual Antiplatelet Therapy (DAPT) duration is critical and varies based on ACS type, revascularization strategy, and bleeding risk.
• Pitfalls:
  • Dismissing chest pain as "non-cardiac" without adequate workup.
  • Over-reliance on a single negative troponin measurement in early presentation.
  • Missing right ventricular infarction (inferior MI with ST elevation in V4R; avoid nitrates, maintain preload).
  • Failure to recognize non-atherosclerotic causes of ischemia (e.g., SCAD, vasospasm).
  • Under-dosing or prematurely discontinuing guideline-directed medical therapies (statins, ACEi/ARBs, beta-blockers).

Recent Updates

• Guidelines:
  • 2019 ESC Guidelines for Chronic Coronary Syndromes (CCS): Emphasis on personalized management, shared decision-making, and the role of non-invasive functional imaging for diagnosis and risk stratification.
  • 2020 ESC Guidelines for NSTE-ACS: Updated recommendations for risk stratification, early invasive strategy in high-risk patients, and DAPT duration.
  • 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization: Consolidated recommendations for PCI and CABG, emphasizing heart team approach and patient-centered care.
• Evidence:
  • ISCHEMIA trial (2020): Demonstrated that an initial invasive strategy (coronary angiography with revascularization) did not reduce the risk of major adverse cardiovascular events (MACE) compared to an initial conservative strategy (optimal medical therapy alone) in patients with stable ischemic heart disease and moderate-to-severe ischemia, as long as optimal medical therapy was achieved. Revascularization improved angina symptoms and quality of life.
  • Novel Lipid-Lowering Therapies: PCSK9 inhibitors (e.g., Evolocumab, Alirocumab) have demonstrated significant LDL-C reduction and CV event reduction in high-risk patients on maximally tolerated statins. Inclisiran, a small interfering RNA, offers BID dosing.
  • Diabetes and CV Outcomes: SGLT2 inhibitors (e.g., Empagliflozin, Dapagliflozin) and GLP-1 receptor agonists (e.g., Liraglutide, Semaglutide) have shown significant cardiovascular benefit (reduction in MACE, heart failure hospitalization, CV death) in patients with type 2 diabetes and established ASCVD or high CV risk.
  • DAPT Duration: Ongoing research refining optimal DAPT duration (e.g., shorter duration in lower-risk patients, longer in higher-risk ischemic but lower bleeding risk patients).
• Controversies:
  • Role of Routine Revascularization in Stable CAD: The ISCHEMIA trial ignited debate on whether routine revascularization is beneficial beyond symptom control in stable patients with moderate-to-severe ischemia who are well-managed on OMT.
  • Optimal Duration of DAPT: Balancing the risk of ischemic events (requiring longer DAPT) vs. bleeding events (favoring shorter DAPT).
  • Management of Patients with No Obstructive Coronary Artery Disease (MINOCA): Understanding underlying mechanisms (e.g., SCAD, myocarditis, Takotsubo) and optimal management strategies.
  • Microvascular Angina: Diagnosis and effective therapeutic strategies for patients with symptoms of ischemia but no obstructive CAD.

Key References

• Guidelines:
  • Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129.
  • Collet JP, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 12;42(14):1289-1367.
  • Knuuti J, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477.
  • Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646.
• Studies:
  • Maron DJ, et al. Primary Results of the ISCHEMIA Trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches). Presented at AHA Scientific Sessions 2019. N Engl J Med. 2020 Apr 9;382(15):1395-1407.
  • Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. (COURAGE trial)
  • Cannon CP, et al. Comparison of early invasive and conservative strategies in patients with unstable angina or non-ST-segment elevation myocardial infarction who are also at high risk of adverse cardiovascular events. N Engl J Med. 2001 Feb 22;344(7):495-502. (TIMI 16 study)
• Reviews:
  • Writing Group Members, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 3;79(17):e263-e421.
  • Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 Aug 22;369(12):1111-23.